Abbott Laboratories (ABT)
Quick ratio
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 7,511,000 | 6,951,000 | 6,532,000 | 7,616,000 | 7,558,000 | 6,987,000 | 6,284,000 | 6,896,000 | 6,709,000 | 7,835,000 | 9,882,000 | 9,882,000 | 9,594,000 | 8,937,000 | 7,675,000 | 9,799,000 | 9,302,000 | 8,658,000 | 8,054,000 | 6,838,000 |
| Short-term investments | US$ in thousands | 222,000 | 331,000 | 312,000 | 351,000 | 230,000 | 232,000 | 367,000 | 383,000 | 338,000 | 320,000 | 288,000 | 288,000 | 313,000 | 353,000 | 483,000 | 450,000 | 390,000 | 286,000 | 318,000 | 310,000 |
| Receivables | US$ in thousands | 10,398,000 | 10,232,000 | 7,327,000 | 6,925,000 | 7,051,000 | 6,854,000 | 6,605,000 | 6,565,000 | 6,499,000 | 6,172,000 | 8,172,000 | 6,218,000 | 6,408,000 | 7,199,000 | 7,179,000 | 6,487,000 | 6,405,000 | 6,113,000 | 6,096,000 | 6,414,000 |
| Total current liabilities | US$ in thousands | 14,582,000 | 13,439,000 | 13,004,000 | 14,157,000 | 14,902,000 | 13,760,000 | 14,021,000 | 13,841,000 | 13,042,000 | 14,350,000 | 15,489,000 | 15,489,000 | 13,365,000 | 12,392,000 | 12,647,000 | 13,105,000 | 12,867,000 | 12,614,000 | 12,462,000 | 11,907,000 |
| Quick ratio | 1.24 | 1.30 | 1.09 | 1.05 | 1.00 | 1.02 | 0.95 | 1.00 | 1.04 | 1.00 | 1.18 | 1.06 | 1.22 | 1.33 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 |
September 30, 2025 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($7,511,000K
+ $222,000K
+ $10,398,000K)
÷ $14,582,000K
= 1.24
Peer comparison
Sep 30, 2025
Company name
Symbol
Quick ratio
Abbott Laboratories
ABT
1.24
CONMED Corporation
CNMD
0.84
Stryker Corporation
SYK
1.04